List of works - J-M Michot

A LYSA Phase Ib Study of tazemetostat (EPZ-6438) plus R-CHOP in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis features

scientific article published on 02 March 2020

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

scientific article

A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.

scientific article published on 22 November 2017

Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody

scientific article published on 18 August 2016

Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study

scientific article

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries

scientific article published on 6 January 2015

Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.

scientific article published on 5 August 2015

Consortium for detection and management of lung damage induced by bleomycin

scientific article

Description of the immune microenvironment of chondrosarcoma and contribution to progression.

scientific article published on 7 December 2016

Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.

scientific article published on 23 April 2018

Distinct efficacy of pegylated-interferon α2a and α2b during treatment of essential thrombocythemia.

scientific article published on 12 February 2013

Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1

scientific article published on 01 June 2018

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

scientific article

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

scientific article published on 12 January 2018

Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy

scientific article

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

scientific article published on 06 June 2019

Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis

scientific article published in December 2017

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

scientific article published on 19 February 2020

Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors

scientific article published on 01 February 2018

From hepatitis C virus infection to B-cell lymphoma.

scientific article published on 10 October 2017

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

scientific article published on 04 December 2018

Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?

scientific article published on 18 October 2019

Haemophagocytic histiocyte in a peripheral blood film.

scientific article

Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review

scientific article published on 03 April 2020

Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency

scientific article

High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result

scientific article published on 28 January 2020

Hodgkin lymphoma: Current and future therapeutic strategies

scientific article published on 27 December 2017

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door

scientific article published on 27 January 2018

Ibrutinib-Induced Neutrophilic Dermatosis

scientific article published on 01 March 2018

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

scientific article published on 10 August 2017

Immune-related bone marrow failure following anti-PD1 therapy.

scientific article published on 17 May 2017

Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies

scientific article published on 15 June 2017

Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease.

scientific article published on 23 September 2014

Immunothérapie des glioblastomes

scientific article published on 01 December 2018

Invasive Geotrichum clavatum fungal infection in an acute myeloid leukaemia patient: a case report and review

scientific article published on 20 April 2014

Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

scientific article

LONG-TERM SURVIVAL IN PATIENTS RESPONDING TO ANTI-PD-1/PD-L1 THERAPY AND DISEASE OUTCOME UPON TREATMENT DISCONTINUATION

scientific article published on 08 October 2018

Late recurrent testicular seminoma: histological evidence is required

scientific article published on 19 May 2015

Le syndrome d’activation lymphohistiocytaire de l’adulte

scientific article published on 05 September 2012

Local treatment for scleritis secondary to Wiskott-Aldrich syndrome

scientific article published on 04 March 2016

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

scientific article

Mixed histiocytosis, a rare cause of stroke

scientific article published on 24 April 2015

Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia

scientific article published on 01 July 2015

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience

scientific article published on 30 May 2018

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

scientific article published on 30 July 2018

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

scientific article published on 30 August 2019

Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.

scientific article published on 21 June 2017

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.

scientific article published in May 2019

Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy

scientific article published on 15 February 2019

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

scientific article

Psychosis, paraplegia and coma revealing methylenetetrahydrofolate reductase deficiency in a 56-year-old woman.

scientific article

Renal toxicities associated with pembrolizumab

scientific article published on 09 November 2018

Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas

scientific article published on 06 April 2020

Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?"

scientific article published on 05 December 2018

Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?"

scientific article published on 01 August 2018

Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study"

scientific article published on 05 October 2018

Reply to: "Mortality due to immunotherapy related hepatitis"

scientific article published on 07 August 2018

Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease

article

Role of radiotherapy in the treatment of NK/T-cell nasal type and primary cerebral lymphomas

scientific article published on 7 September 2016

Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.

scientific article published on 09 April 2015

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

scientific article published on 10 May 2017

Severe gastro-intestinal angiodysplasia in context of Heyde's syndrome durably cured after aortic valve replacement

scientific article published on 10 December 2011

Successful outcome of a corticodependent henoch-schönlein purpura adult with rituximab

scientific article published on April 2014

The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.

scientific article published on 28 April 2017

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

scientific article published on 17 October 2018

Usefulness of video-laryngoscopy with the Airway Scope for intubation performance and learning: an experimental manikin controlled study.

scientific article published on 26 August 2016

Very prolonged liposomal amphotericin B use leading to a lysosomal storage disease.

scientific article published on 12 April 2014

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

scientific article published on 03 December 2019

[Disseminated varicella-zoster virus infection with hemorrhagic gastritis during the course of chronic lymphocytic leukemia: case report and literature review]

scientific article published on 14 June 2013

[Immune-related adverse events after immune checkpoints inhibitors in 2019: An update]

scientific article published on 24 October 2019

[Leptospirosis: an unusual etiology of anterior uveitis]

scientific article published on 26 March 2007

List of works by J-M Michot

A LYSA Phase Ib Study of tazemetostat (EPZ-6438) plus R-CHOP in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis features

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.

Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody

Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries

Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.

Consortium for detection and management of lung damage induced by bleomycin

Description of the immune microenvironment of chondrosarcoma and contribution to progression.

Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.

Distinct efficacy of pegylated-interferon α2a and α2b during treatment of essential thrombocythemia.

Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors

From hepatitis C virus infection to B-cell lymphoma.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?

Haemophagocytic histiocyte in a peripheral blood film.

Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review

Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency

High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result

Hodgkin lymphoma: Current and future therapeutic strategies

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door

Ibrutinib-Induced Neutrophilic Dermatosis

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Immune-related bone marrow failure following anti-PD1 therapy.

Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies

Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease.

Immunothérapie des glioblastomes

Invasive Geotrichum clavatum fungal infection in an acute myeloid leukaemia patient: a case report and review

Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

LONG-TERM SURVIVAL IN PATIENTS RESPONDING TO ANTI-PD-1/PD-L1 THERAPY AND DISEASE OUTCOME UPON TREATMENT DISCONTINUATION

Late recurrent testicular seminoma: histological evidence is required

Le syndrome d’activation lymphohistiocytaire de l’adulte

Local treatment for scleritis secondary to Wiskott-Aldrich syndrome

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Mixed histiocytosis, a rare cause of stroke

Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.

Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

Psychosis, paraplegia and coma revealing methylenetetrahydrofolate reductase deficiency in a 56-year-old woman.

Renal toxicities associated with pembrolizumab

Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas

Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?"

Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?"

Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study"

Reply to: "Mortality due to immunotherapy related hepatitis"

Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease

Role of radiotherapy in the treatment of NK/T-cell nasal type and primary cerebral lymphomas

Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

Severe gastro-intestinal angiodysplasia in context of Heyde's syndrome durably cured after aortic valve replacement

Successful outcome of a corticodependent henoch-schönlein purpura adult with rituximab

The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Usefulness of video-laryngoscopy with the Airway Scope for intubation performance and learning: an experimental manikin controlled study.

Very prolonged liposomal amphotericin B use leading to a lysosomal storage disease.

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

[Disseminated varicella-zoster virus infection with hemorrhagic gastritis during the course of chronic lymphocytic leukemia: case report and literature review]

[Immune-related adverse events after immune checkpoints inhibitors in 2019: An update]

[Leptospirosis: an unusual etiology of anterior uveitis]